Radiation sickness treatment provider will ramp up supply in Europe

Published



One medical provider of anti-radiation treatments has decided to boost its production and sales in Europe amid growing concerns regarding nuclear power and weapons.

Partner Therapeutics, the creator of the radiation sickness treatment drug Leukine, said it was increasing its drug production in Europe. The pharmaceutical company said it was reaching out to the World Health Organization and other entities to provide the necessary tools if nuclear war broke out.
<mediadc-video-embed data-state="{"cms.site.owner":{"_ref":"00000161-3486-d333-a9e9-76c6fbf30000","_type":"00000161-3461-dd66-ab67-fd6b93390000"},"cms.content.publishDate":1648556713341,"cms.content.publishUser":{"_ref":"0000017c-2d8e-d3f3-a7fc-7ffef6720000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"cms.content.updateDate":1648556713341,"cms.content.updateUser":{"_ref":"0000017c-2d8e-d3f3-a7fc-7ffef6720000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"rawHtml":"

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.